MX2022010317A - Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision. - Google Patents
Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision.Info
- Publication number
- MX2022010317A MX2022010317A MX2022010317A MX2022010317A MX2022010317A MX 2022010317 A MX2022010317 A MX 2022010317A MX 2022010317 A MX2022010317 A MX 2022010317A MX 2022010317 A MX2022010317 A MX 2022010317A MX 2022010317 A MX2022010317 A MX 2022010317A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- adrenergic receptor
- pharmaceutical compositions
- receptor agonists
- improving vision
- Prior art date
Links
- 230000004377 improving vision Effects 0.000 title abstract 2
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 title 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000007 visual effect Effects 0.000 abstract 3
- 208000001491 myopia Diseases 0.000 abstract 2
- 230000004379 myopia Effects 0.000 abstract 2
- 241000284156 Clerodendrum quadriloculare Species 0.000 abstract 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 abstract 1
- 230000004313 glare Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000004297 night vision Effects 0.000 abstract 1
- 201000010041 presbyopia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062979214P | 2020-02-20 | 2020-02-20 | |
| PCT/US2021/018906 WO2021168349A1 (en) | 2020-02-20 | 2021-02-19 | Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010317A true MX2022010317A (es) | 2023-01-24 |
Family
ID=74875311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010317A MX2022010317A (es) | 2020-02-20 | 2021-02-19 | Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210260041A1 (enExample) |
| EP (1) | EP4106728A1 (enExample) |
| JP (1) | JP2023514732A (enExample) |
| KR (1) | KR20220157392A (enExample) |
| CN (1) | CN115443125A (enExample) |
| AU (1) | AU2021224232A1 (enExample) |
| BR (1) | BR112022016730A2 (enExample) |
| CA (1) | CA3168767A1 (enExample) |
| IL (1) | IL295782A (enExample) |
| MX (1) | MX2022010317A (enExample) |
| TW (1) | TW202139998A (enExample) |
| WO (1) | WO2021168349A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022182740A1 (en) | 2021-02-24 | 2022-09-01 | Ocular Therapeutix, Inc. | Intracanalicular depot inserter device |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| KR102337046B1 (ko) | 2010-01-22 | 2021-12-08 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| WO2014159576A1 (en) * | 2013-03-14 | 2014-10-02 | Allergan, Inc. | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes |
| ES2751681T3 (es) | 2013-03-15 | 2020-04-01 | Allergan Inc | Implante intraocular que contiene prostamida |
| EP2978406A1 (en) | 2013-03-27 | 2016-02-03 | Forsight Vision5, Inc. | Bimatoprost ocular silicone inserts and methods of use thereof |
| WO2014165308A2 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| EP3840750A1 (en) * | 2018-08-21 | 2021-06-30 | Allergan, Inc. | The use of alpha-2-adrenergic receptor agonists for improving vision |
-
2021
- 2021-02-19 JP JP2022550240A patent/JP2023514732A/ja active Pending
- 2021-02-19 EP EP21712314.0A patent/EP4106728A1/en not_active Withdrawn
- 2021-02-19 TW TW110105859A patent/TW202139998A/zh unknown
- 2021-02-19 MX MX2022010317A patent/MX2022010317A/es unknown
- 2021-02-19 US US17/180,532 patent/US20210260041A1/en not_active Abandoned
- 2021-02-19 KR KR1020227032439A patent/KR20220157392A/ko not_active Withdrawn
- 2021-02-19 CA CA3168767A patent/CA3168767A1/en active Pending
- 2021-02-19 CN CN202180027733.2A patent/CN115443125A/zh active Pending
- 2021-02-19 AU AU2021224232A patent/AU2021224232A1/en not_active Abandoned
- 2021-02-19 WO PCT/US2021/018906 patent/WO2021168349A1/en not_active Ceased
- 2021-02-19 IL IL295782A patent/IL295782A/en unknown
- 2021-02-19 BR BR112022016730A patent/BR112022016730A2/pt not_active Application Discontinuation
-
2024
- 2024-02-12 US US18/439,468 patent/US20240335425A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021224232A1 (en) | 2022-10-13 |
| JP2023514732A (ja) | 2023-04-07 |
| KR20220157392A (ko) | 2022-11-29 |
| CA3168767A1 (en) | 2021-08-26 |
| TW202139998A (zh) | 2021-11-01 |
| US20210260041A1 (en) | 2021-08-26 |
| BR112022016730A2 (pt) | 2022-11-08 |
| EP4106728A1 (en) | 2022-12-28 |
| WO2021168349A1 (en) | 2021-08-26 |
| US20240335425A1 (en) | 2024-10-10 |
| CN115443125A (zh) | 2022-12-06 |
| IL295782A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550882A1 (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| PH12021550620A1 (en) | Ophthalmic composition for treatment of dry eye disease | |
| Raiskup-Wolf et al. | Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results | |
| US20200237916A1 (en) | Ophthalmic formulation and method for ameliorating presbyopia | |
| Nguyen et al. | EyePrintPRO therapeutic scleral contact lens: indications and outcomes | |
| MX2020011301A (es) | Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares. | |
| KR101789019B1 (ko) | 수성 점안액 | |
| PH12021550372A1 (en) | The use of alpha-2-adrenergic receptor agonists for improving vision | |
| MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
| MX2021013447A (es) | Composiciones y procedimientos para el tratamiento de enfermedades oculares. | |
| TW200621236A (en) | Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases | |
| MX2020011535A (es) | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. | |
| Vereertbrugghen et al. | Hyaluronate protects from benzalkonium chloride-induced ocular surface toxicity | |
| EP4652999A3 (en) | Liquid depot for non-invasive sustained delivery of agents to the eye | |
| MX2023002946A (es) | Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida. | |
| PH12022553289A1 (en) | Ophthalmic nanoemulsion compositions | |
| BR112022016730A2 (pt) | Composições farmacêuticas de agonistas de receptor alfa-2-adrenérgico e seu uso para melhorar a visão | |
| WO2025030161A8 (en) | Rexinoids for treatment of ocular diseases | |
| GB0521351D0 (en) | Modulation of TRPV expression levels | |
| Jagadeesh et al. | Visual performance with changes in eccentricity in PROSE device: A case report | |
| Lorente‐Velázquez et al. | Straylight and contrast sensitivity after corneal refractive therapy | |
| HK40107760A (en) | Methods and compositions for treating mydriasis, glaucoma, and other ocular conditions | |
| WO2024211322A3 (en) | Ripasudil based ophthalmic treatments | |
| Woods et al. | The impact of saline rinsing on solution-induced corneal staining (SICS) | |
| WO2022234339A3 (en) | 5-ht2a and/or 5-ht2c receptor agonists |